Gallus Biopharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann Pick Type B Disease - - BioPharm International

ADVERTISEMENT

Gallus Biopharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann Pick Type B Disease



Gallus Biopharmaceuticals, has signed a development and manufacturing supply agreement with Genzyme, a Sanofi company. As part of the multiyear agreement Gallus will provide process and method development, scale-up, clinical supply, and preparation for commercial manufacturing for an infused protein-based therapy targeting the rare disease, Niemann-Pick type B.

The firm based in St. Louis, Missouri, was established in 2010 and acquired a commercial biopharmaceutical manufacturing facility from Johnson & Johnson Centocor division in 2011. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally.

Source: Gallus Biopharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines

Click here